Here’s a startling fact: a significant number of breast cancers are being diagnosed in women under 40, a group often overlooked in routine screening recommendations. But here’s where it gets controversial—these younger women not only represent a substantial portion of cases but also face more aggressive forms of the disease. Could our current screening guidelines be missing the mark? Let’s dive in.
A recent retrospective review from a large community imaging practice in New York revealed that women under 50 accounted for about a quarter of all breast cancer diagnoses, with a notable number occurring in those under 40. Among nearly 1,800 cases in women aged 18 to 49, 23% were in women under 40—a group not typically advised to undergo regular screening. Stamatia Destounis, MD, of Elizabeth Wende Breast Care in Rochester, New York, presented these findings at the Radiological Society of North America (RSNA) annual meeting in Chicago.
What’s even more alarming is the nature of these cancers. Younger patients tended to have more aggressive tumors compared to those aged 40 to 49. For instance, 84.7% of tumors in women under 40 were invasive, compared to 77% in the older group. Additionally, they had higher rates of triple-negative disease (13.5% vs. 8.5%) and grade 3 tumors (46% vs. 29%). And this is the part most people miss—these statistics highlight a critical gap in early detection strategies for younger women.
Dr. Destounis emphasized, ‘This is striking because it shows that younger women not only carry a stable and substantial share of the breast cancer burden, but their tumors are often biologically aggressive.’ Her findings strongly suggest the need for earlier or more intensive screening for high-risk younger populations. But how do we identify these women? And what’s the best way to intervene early?
National data from the CDC and the American Cancer Society have already flagged a rising incidence of breast cancer in younger women. Dr. Destounis explained, ‘Our purpose was to reevaluate age-based screening thresholds and risk stratification strategies, and understand age-specific tumor behavior for these younger patients.’ Yet, current guidelines from the U.S. Preventive Services Task Force recommend mammography screening every other year starting at age 40, while the American Cancer Society suggests starting annual screening by age 45, with an option to begin at 40.
The study analyzed 1,798 breast cancers diagnosed in 1,290 women aged 18 to 49 at seven outpatient facilities in Western New York. These cases represented 20% to 24% of all breast tumors diagnosed during the 2014–2024 study period. The majority of patients were white (90%), and 21% had a family history of breast cancer. Interestingly, 41% of cancers were detected through screening, while 59% were found during diagnostic evaluations. The average tumor size was 22 mm for invasive cancers and 27 mm for non-invasive ones.
Among the cases, 80.6% were invasive, and a third were grade 3. Most tumors (61.6%) were hormone receptor (HR)-positive/HER2-negative, while 9.7% were triple-negative. When asked about BRCA gene mutations in women under 40, Dr. Destounis noted, ‘We recommend genetic testing for all newly diagnosed breast cancer patients, especially the young ones.’ However, she added, ‘Most of these patients were not BRCA1 or 2 positive, though we did find other mutations like PALB2 and PTEN.’
Here’s the bold question: Should we reconsider screening guidelines to include younger women, or is the current approach sufficient? The data clearly shows that younger women are not only at risk but also face more aggressive forms of breast cancer. What do you think? Should screening start earlier, or are there other factors we should consider? Let’s spark a conversation in the comments below!
